netFormulary NHS
Bedfordshire and Luton Joint Formulary
Bedford Hospital NHS Trust
Bedfordshire CCG
Luton & Dunstable University Hospital NHS Foundation Trust
Luton CCG
 Search
 Formulary Chapter 13: Skin - Full Chapter
Notes:

Any drug not listed on the Formulary should be considered Non-Formulary - Not recommended for prescribing

Chapter Links...
 Details...
13.05.03  Expand sub section  Drugs affecting the immune response
Adalimumab 40mg (Humira®)
(Dermatology)
View adult BNF View SPC online View childrens BNF
Restricted Drug Restricted
Red
High Cost Medicine
FOR ALL PRESCRIBING – Blueteq or High cost drug form required – see link from Formulary homepage.

Approved in accordance with NICE TA146 & TA455.

 
Link  MHRA Drug Safety Update (April 2014) - Tumour necrosis factor alpha inhibitors
Link  NICE TA146: Adalimumab for the treatment of adults with psoriasis
Link  NICE TA455:Adalimumab, etanercept and ustekinumab for treating plaque psoriasis in children and young people
   
Adalimumab 40mg (Imraldi®)
(Dermatology)
View adult BNF View SPC online View childrens BNF
Restricted Drug Restricted
Red

FOR ALL PRESCRIBING – Blueteq or High cost drug form required – see link from Formulary homepage.

Approved in accordance with NICE TA146 & TA455.

 
Link  MHRA Drug Safety Update (April 2014) - Tumour necrosis factor alpha inhibitors
Link  NICE TA146: Adalimumab for the treatment of adults with psoriasis
Link  NICE TA455:Adalimumab, etanercept and ustekinumab for treating plaque psoriasis in children and young people
   
Apremilast (Otezla®)
View adult BNF View SPC online View childrens BNF
Restricted Drug Restricted
Red
High Cost Medicine
FOR ALL PRESCRIBING – Blueteq or High cost drug form required – see link from Formulary homepage.

Specialist consultant prescribing according to NICE TA419.

10mg, 20mg, 30mg tablets. 
Link  NICE TA419: Apremilast for treating moderate to severe plaque psoriasis
   
Cytotoxic Drug Azathioprine
View adult BNF View SPC online View childrens BNF
Formulary
Amber
See section 8.2.1 
   
Brodalumab 210mg (Kyntheum®)
(Injection)
View adult BNF View SPC online View childrens BNF
Restricted Drug Restricted
Red
High Cost Medicine

FOR ALL PRESCRIBING – Blueteq or High cost drug form required – see link from Formulary homepage.

Restricted - for consultant dermatologist prescribing in line with NICE TA511.

 
Link  NICE TA511: Brodalumab for treating moderate to severe plaque psoriasis
   
Certolizumab pegol 200 mg Injection (Cimzia® Pre-filled Pen or Pre-filled Syringe)
View adult BNF View SPC online View childrens BNF
Restricted Drug Restricted
Red
High Cost Medicine
CCG
BlueTeq

FOR ALL PRESCRIBING - Blueteq or High Cost Drug Form required - see link from Formulary Homepage

RESTRICTED for Consultant Dermatologist prescribing in line with the following NICE TA(s):

 
Link  NICE TA574 Certolizumab pegol for treating moderate to severe plaque psoriasis
   
Ciclosporin
View adult BNF View SPC online View childrens BNF
Formulary
Amber
See section 8.2.1 
   
Etanercept (Enbrel®)
View adult BNF View SPC online View childrens BNF
Restricted Drug Restricted
Red
High Cost Medicine
FOR ALL PRESCRIBING – Blueteq or High cost drug form required – see link from Formulary homepage.

50mg/1mL Pre-filled Pen (Benepali)
50mg/1mL Pre-filled Syringe (Benepali)

10mg/1mL, 25mg/1mL & 50mg/1mL Injection (Enbrel)
25mg/1mL & 50mg/1mL Pre-filled Syringe (Enbrel)

Approved in accordance with NICE TA103 & TA455 for the treatment of severe plaque psoriasis.

Restricted - must be initiated by a Dermatology consultant only and must be prescribed by generic and brand name  
Link  MHRA Drug Safety Update (April 2014) - Tumour necrosis factor alpha inhibitors
Link  NICE TA103: Psoriasis - efalizumab and etanercept
Link  NICE TA455:Adalimumab, etanercept and ustekinumab for treating plaque psoriasis in children and young people
   
Infliximab (Remicade®)
View adult BNF View SPC online View childrens BNF
Formulary
Red
High Cost Medicine
FOR ALL PRESCRIBING – Blueteq or High cost drug form required – see link from Formulary homepage.

Approved in accordance with NICE TA134 for the treatment of plaque psoriasis.

 
Link  MHRA Drug Safety Update (April 2014) - Tumour necrosis factor alpha inhibitors
Link  NICE TA134: Infliximab for psoriasis
   
Ixekizumab 80mg (Taltz® )
(Pre-filled pen or syringe)
View adult BNF View SPC online View childrens BNF
Restricted Drug Restricted
Red
High Cost Medicine

FOR ALL PRESCRIBING – Blueteq or High cost drug form required – see link from Formulary homepage.
To be prescribed by specialists in accordance with NICE TA442 and TA537.

 
Link  NICE TA442: Ixekizumab for treating moderate to severe plaque psoriasis
Link  NICE TA537: Ixekizumab for treating active psoriatic arthritis after inadequate response to DMARDs
   
Cytotoxic Drug Methotrexate
View adult BNF View SPC online View childrens BNF
Formulary
Amber
See section 10.1.3 
   
Pimecrolimus 1% (Elidel®)
(Cream)
View adult BNF View SPC online View childrens BNF
Formulary
Amber
Approved in accordance with NICE TA82 for the treatment of mild atopic eczema. For more information click the link below.
 
Link  NICE TA82: Pimecrolimus and tacrolimus for atopic dermatitis (eczema)
   
Risankizumab  (Skyrizi®)
(75 mg solution for injection in pre-filled syringe)
View adult BNF View SPC online View childrens BNF
Restricted Drug Restricted
Red
BlueTeq

FOR ALL PRESCRIBING - Blueteq or High Cost Drug Form required - see link from Formulary Homepage.

Restricted to Specialist Prescribing in accordance with the following NICE TA(s):-

 

 
Link  NICE TA 596 Risankizumab for treating moderate to severe plaque psoriasis
   
Secukinumab 150mg (Cosentyx®)
(Pre-filled pen or syringe)
View adult BNF View SPC online View childrens BNF
Restricted Drug Restricted
Red
High Cost Medicine
FOR ALL PRESCRIBING – Blueteq or High cost drug form required – see link from Formulary homepage.

Approved for prescribing by Dermatology consultants in accordance with NICE TA350 for the treatment of plaque psoriasis. 
Link  NICE TA350: Secukinumab for treating moderate to severe plaque psoriasis
   
Tacrolimus (Protopic®)
View adult BNF View SPC online View childrens BNF
Formulary
Amber
0.03% & 0.1% Ointment

Approved in accordance with NICE TA82 for the treatment of mild atopic eczema.  
Link  NICE TA82: Pimecrolimus and tacrolimus for atopic dermatitis (eczema)
   
Tildrakizumab (Ilumetri 100mg®)
(Injection)
View adult BNF View SPC online View childrens BNF
Restricted Drug Restricted
Red
High Cost Medicine
BlueTeq

FOR ALL PRESCRIBING - Blueteq or High Cost Drug Form Required - see link from Formulary Home Page. 

Approved in accordance NICE TA (s) below:-

 
Link  NICE TA 575 Tildrakizumab for treating moderate to severe plaque psoriasis
   
Ustekinumab 45mg, 90mg (Stelara®)
(Pre-filled syringe or injection)
View adult BNF View SPC online View childrens BNF
Restricted Drug Restricted
Red
High Cost Medicine
FOR ALL PRESCRIBING – Blueteq or High cost drug form required – see link from Formulary homepage.

Approved in accordance with NICE TA180, TA455 and TA456.

 
Link  MHRA Drug Safety Update (January 2015) - Ustekinumab (Stelara): risk of exfoliative dermatitis
Link  NICE TA180: Psoriasis - ustekinumab
Link  NICE TA455:Adalimumab, etanercept and ustekinumab for treating plaque psoriasis in children and young people
   
 ....
 Non Formulary Items
Efalizumab  (Raptiva®)

View adult BNF View SPC online View childrens BNF
Non Formulary
 
  
Key
note Notes
Section Title Section Title (top level)
Section Title Section Title (sub level)
First Choice Item First Choice item
Non Formulary Item Non Formulary section
Restricted Drug
Restricted Drug
Unlicensed Drug
Unlicensed
Track Changes
Display tracking information
click to search medicines.org.uk
Link to adult BNF
click to search medicines.org.uk
Link to children's BNF
click to search medicines.org.uk
Link to SPCs
SMC
Scottish Medicines Consortium
Cytotoxic Drug
Cytotoxic Drug
CD
Controlled Drug
High Cost Medicine
High Cost Medicine
Cancer Drugs Fund
Cancer Drugs Fund
NHSE
NHS England
Homecare
Homecare
CCG
CCG

Traffic Light Status Information

Status Description

Red

RED - Hospital only – to be prescribed by a specialist and supplied from secondary care ONLY throughout treatment  

Amber

Amber medicines are considered suitable for GP prescribing following specialist initiation.  

Green

These medicines are appropriate for initiation in both primary and secondary care. Prescribing is appropriate within licensed or local recommendations   

Amber SCG

Shared Care - these medicines require specialist initiation and stabilisation. Ongoing division of responsibility for drug and disease monitoring between specialist and GP by a Shared Care Guideline (SCG). If no SCG in place status reverts to red.   

Black

A decision has been made by either or both the local or national NHS not to routinely commission this preparation for its licensed indications. Do not prescribe.   

netFormulary